UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume – Time to Buy?

UCB SA (OTCMKTS:UCBJF) saw an uptick in trading volume on Monday . 7,964 shares traded hands during trading, an increase of 1,012% from the previous session’s volume of 716 shares.The stock last traded at $278.42 and had previously closed at $280.8525.

Analyst Ratings Changes

Several research firms have recently weighed in on UCBJF. Wolfe Research began coverage on shares of UCB in a report on Monday, February 23rd. They set an “outperform” rating for the company. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a report on Monday, February 16th. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy”.

UCB Stock Performance

The firm’s 50 day simple moving average is $299.95 and its 200-day simple moving average is $295.42. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.